about
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanismsMifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesityPPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney diseaseEffect of pioglitazone on survival and renal function in a mouse model of polycystic kidney diseaseInsulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.The impact of type 2 diabetes and antidiabetic drugs on cancer cell growthSynergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.Emerging therapy for adrenocortical carcinoma.Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancerPeroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.Influence of cardiorespiratory fitness on PPARG mRNA expression using monozygotic twin case controlThiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.Effects of PPARγ agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo.Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.Dietary modulation of inflammation-induced colorectal cancer through PPARγ.Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours.PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.A PPAR-gamma agonist protects from radiation-induced intestinal toxicity.PPARγ agonist beyond glucose lowering effect.Diabetes-induced mechanophysiological changes in the small intestine and colon.Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinedionesUnique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment.Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators
P2860
Q27026813-34EEA93C-EA1D-446C-9C93-B2346299BC3EQ27302419-B35DC588-A3B9-485D-B0E4-E8782D008F1FQ28742454-603BA028-5B4E-4604-AD0A-0DD046326E40Q33637525-D1177367-C41B-4472-A1BA-9679F26B0347Q33688576-8145F2BA-64F5-4187-84BD-0BA9E9CAF860Q33809071-42ACC128-F67D-4157-9EAB-FFAA8D06D535Q33921641-5AC00EC8-0305-466A-8445-6FCC777320F4Q34095570-E49904BC-2D58-4468-9C83-9363E59A0701Q35011149-C4EE8107-1738-437E-9AE1-291E13298F5FQ35018399-16A2E5E7-F4A9-4F85-A904-4E7F7168529EQ35034870-7650A0ED-CFE3-4A53-964F-658A5FAD2F76Q35051779-AC8E50E6-EB30-40DA-AC9F-EC2B5B9318F0Q35297540-2CA3EFCE-ED39-4262-AA99-5BE249F0A2E7Q35565610-4D24A050-DE59-451A-865C-9A92E39F3A11Q36375151-1BC92098-173B-453E-9475-FA1DD9084DC3Q36560240-8478CBEA-2BCF-4A7D-B986-C87BF2A155FCQ37166674-3B87224F-F9B3-4A9D-A99E-25CB4E330DDFQ37188588-2FB7B8E9-4D09-421F-AA24-2EE52BB613BCQ37641546-C357BC4E-33A7-4567-81A3-4C744765D474Q37698546-754BB5AA-CD2D-4507-85DA-4CBF6DCA7E3FQ37857704-87637595-7673-402F-BD02-BCAA2134F006Q39427195-0270E009-2F5D-47B2-9FBD-F83FE4575825Q39514941-18E70F1F-CE0F-44D4-B205-78D1D080039DQ39860554-B63EED0F-65E4-45C7-90B9-CA0FA50F36B0Q47709745-2F274D62-20DF-4C39-9952-467D05490EFCQ49367260-3F4A8599-D4AD-40CC-B8C1-B2F138EE84FBQ55177909-450F165A-21F4-4985-BEDB-33CEC8DA1429Q58795617-4E628D23-3208-4F4D-9C59-D1C0535C0F3F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thiazolidinediones as anti-cancer agents.
@en
Thiazolidinediones as anti-cancer agents.
@nl
type
label
Thiazolidinediones as anti-cancer agents.
@en
Thiazolidinediones as anti-cancer agents.
@nl
prefLabel
Thiazolidinediones as anti-cancer agents.
@en
Thiazolidinediones as anti-cancer agents.
@nl
P2093
P2860
P1433
P1476
Thiazolidinediones as anti-cancer agents.
@en
P2093
C Michael Hart
Carmelo Blanquicett
Jesse Roman
P2860
P577
2008-01-01T00:00:00Z